Pfizer Inc (PFE) Stock Analysis

PFE- NYSE (USA) Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK
Pfizer Inc

Currently 1/5

Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$32.38

0(0%) Volume: 23,816,318 1:01AM EST

Avg Vol (1m): 27,387,378

2 Medium Warning Signs 4 Good Signs

Market Cap	196.49 B	P/E(ttm)	27.93
Enterprise Value	194.3 B	P/B	3.11

$32.38 (1y: +10%)

Today's Updates:

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

Financial Strength : 6/10

		vs industry	vs history
Cash to Debt	N/A	PFE's Cash to Debt is ranked higher than 80% of the 782 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.69 vs. PFE: N/A ) Ranked among companies with meaningful Cash to Debt only.	PFE' s Cash to Debt Range Over the Past 10 Years Min: 0.3 Med: 0.94 Max: N/A Current: N/A
Equity to Asset	0.36	PFE's Equity to Asset is ranked lower than 84% of the 720 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 0.63 vs. PFE: 0.36 ) Ranked among companies with meaningful Equity to Asset only.	PFE' s Equity to Asset Range Over the Past 10 Years Min: 0.36 Med: 0.47 Max: 0.62 Current: 0.36 0.36 - 0.62
Interest Coverage	11.58	PFE's Interest Coverage is ranked lower than 71% of the 632 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 92.87 vs. PFE: 11.58 ) Ranked among companies with meaningful Interest Coverage only.	PFE' s Interest Coverage Range Over the Past 10 Years Min: 5.27 Med: 9.95 Max: 18.94 Current: 11.58 5.27 - 18.94

WACC vs ROIC

9.66%

13.83%

WACC

ROIC

Profitability & Growth : 6/10

		vs industry	vs history
Operating margin (%)	25.99	PFE's Operating margin (%) is ranked higher than 89% of the 733 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 8.68 vs. PFE: 25.99 ) Ranked among companies with meaningful Operating margin (%) only.	PFE' s Operating margin (%) Range Over the Past 10 Years Min: 14.53 Med: 22.93 Max: 29.44 Current: 25.99 14.53 - 29.44
Net-margin (%)	13.50	PFE's Net-margin (%) is ranked higher than 74% of the 734 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 5.95 vs. PFE: 13.50 ) Ranked among companies with meaningful Net-margin (%) only.	PFE' s Net-margin (%) Range Over the Past 10 Years Min: 12.67 Med: 16.8 Max: 42.65 Current: 13.5 12.67 - 42.65
ROE (%)	11.12	PFE's ROE (%) is ranked higher than 64% of the 758 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 6.80 vs. PFE: 11.12 ) Ranked among companies with meaningful ROE (%) only.	PFE' s ROE (%) Range Over the Past 10 Years Min: 9.29 Med: 12.16 Max: 27.93 Current: 11.12 9.29 - 27.93
ROA (%)	4.19	PFE's ROA (%) is ranked higher than 54% of the 789 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 3.58 vs. PFE: 4.19 ) Ranked among companies with meaningful ROA (%) only.	PFE' s ROA (%) Range Over the Past 10 Years Min: 4.05 Med: 6.22 Max: 12.3 Current: 4.19 4.05 - 12.3
ROC (Joel Greenblatt) (%)	54.36	PFE's ROC (Joel Greenblatt) (%) is ranked higher than 85% of the 778 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 13.18 vs. PFE: 54.36 ) Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.	PFE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years Min: 40.74 Med: 57.28 Max: 126.81 Current: 54.36 40.74 - 126.81
Revenue Growth (3Y)(%)	4.70	PFE's Revenue Growth (3Y)(%) is ranked lower than 53% of the 602 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 5.50 vs. PFE: 4.70 ) Ranked among companies with meaningful Revenue Growth (3Y)(%) only.	PFE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years Min: -2.5 Med: 3.8 Max: 18.1 Current: 4.7 -2.5 - 18.1
EBITDA Growth (3Y)(%)	-13.50	PFE's EBITDA Growth (3Y)(%) is ranked lower than 84% of the 570 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 10.00 vs. PFE: -13.50 ) Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.	PFE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years Min: -13.5 Med: 4.3 Max: 35.6 Current: -13.5 -13.5 - 35.6
EPS Growth (3Y)(%)	-10.80	PFE's EPS Growth (3Y)(%) is ranked lower than 74% of the 533 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 8.20 vs. PFE: -10.80 ) Ranked among companies with meaningful EPS Growth (3Y)(%) only.	PFE' s EPS Growth (3Y)(%) Range Over the Past 10 Years Min: -26.8 Med: -0.8 Max: 90.5 Current: -10.8 -26.8 - 90.5

GuruFocus has detected 2 Warning Signs with Pfizer Inc $PFE.

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

» PFE's 10-Y Financials

Financials

Revenue & Net Income

Cash & Debt

Oprt. Cash Flow & Free Cash Flow

Oprt. Cash Flow & Net Income

» PFE's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades

Q1 2016

Q2 2016

Q3 2016

Q4 2016

» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Select Gurus: | Basic | Premium

| Premium Plus

No Entry found in the selected group of Gurus. You can

1. Modify your Personalized List of Gurus, or
2. Click on Premium above to check out all the Gurus, or
3. Click on Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry:	Drug Manufacturers » Drug Manufacturers - Major NAICS: 325412 SIC: 2834
Compare:	NYSE:MRK, OTCPK:NVSEF, NYSE:SNY, NYSE:ABBV, OTCPK:GLAXF, OTCPK:BAYZF, NYSE:LLY, NYSE:BMY, NYSE:JNJ, NYSE:AZN, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF » details
Traded in other countries:	PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, PFZ.UK,

Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.

Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.

From the Gabelli Dividend Growth Fund second quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Ratios

		vs industry	vs history
P/E(ttm)	27.93	PFE's P/E(ttm) is ranked higher than 50% of the 532 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 27.63 vs. PFE: 27.93 ) Ranked among companies with meaningful P/E(ttm) only.	PFE' s P/E(ttm) Range Over the Past 10 Years Min: 7.68 Med: 16.09 Max: 34.77 Current: 27.93 7.68 - 34.77
Forward P/E	12.53	PFE's Forward P/E is ranked higher than 71% of the 68 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 16.89 vs. PFE: 12.53 ) Ranked among companies with meaningful Forward P/E only.	N/A
PE(NRI)	27.93	PFE's PE(NRI) is ranked higher than 50% of the 533 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 27.65 vs. PFE: 27.93 ) Ranked among companies with meaningful PE(NRI) only.	PFE' s PE(NRI) Range Over the Past 10 Years Min: 9.83 Med: 19.12 Max: 34.43 Current: 27.93 9.83 - 34.43
Price/Owner Earnings (ttm)	24.14	PFE's Price/Owner Earnings (ttm) is ranked higher than 65% of the 289 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 31.92 vs. PFE: 24.14 ) Ranked among companies with meaningful Price/Owner Earnings (ttm) only.	PFE' s Price/Owner Earnings (ttm) Range Over the Past 10 Years Min: 5.44 Med: 10.88 Max: 36.49 Current: 24.14 5.44 - 36.49
P/B	3.11	PFE's P/B is ranked lower than 53% of the 753 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 2.85 vs. PFE: 3.11 ) Ranked among companies with meaningful P/B only.	PFE' s P/B Range Over the Past 10 Years Min: 1.32 Med: 2.4 Max: 3.57 Current: 3.11 1.32 - 3.57
P/S	3.75	PFE's P/S is ranked lower than 58% of the 710 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 2.90 vs. PFE: 3.75 ) Ranked among companies with meaningful P/S only.	PFE' s P/S Range Over the Past 10 Years Min: 1.72 Med: 3.62 Max: 4.75 Current: 3.75 1.72 - 4.75
PFCF	22.89	PFE's PFCF is ranked higher than 51% of the 201 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 23.18 vs. PFE: 22.89 ) Ranked among companies with meaningful PFCF only.	PFE' s PFCF Range Over the Past 10 Years Min: 5.02 Med: 13.1 Max: 23.68 Current: 22.89 5.02 - 23.68
POCF	20.04	PFE's POCF is ranked lower than 56% of the 268 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 17.44 vs. PFE: 20.04 ) Ranked among companies with meaningful POCF only.	PFE' s POCF Range Over the Past 10 Years Min: 4.55 Med: 11.75 Max: 20.73 Current: 20.04 4.55 - 20.73
EV-to-EBIT	20.61	PFE's EV-to-EBIT is ranked higher than 51% of the 538 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 20.50 vs. PFE: 20.61 ) Ranked among companies with meaningful EV-to-EBIT only.	PFE' s EV-to-EBIT Range Over the Past 10 Years Min: 6.7 Med: 14.4 Max: 28.8 Current: 20.61 6.7 - 28.8
EV-to-EBITDA	13.21	PFE's EV-to-EBITDA is ranked higher than 65% of the 563 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 17.04 vs. PFE: 13.21 ) Ranked among companies with meaningful EV-to-EBITDA only.	PFE' s EV-to-EBITDA Range Over the Past 10 Years Min: 4.9 Med: 9.3 Max: 17.3 Current: 13.21 4.9 - 17.3
Shiller P/E	20.72	PFE's Shiller P/E is ranked higher than 82% of the 157 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 46.15 vs. PFE: 20.72 ) Ranked among companies with meaningful Shiller P/E only.	PFE' s Shiller P/E Range Over the Past 10 Years Min: 9.12 Med: 16.31 Max: 21.51 Current: 20.72 9.12 - 21.51
Days Inventory	224.38	PFE's Days Inventory is ranked lower than 86% of the 684 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 114.19 vs. PFE: 224.38 ) Ranked among companies with meaningful Days Inventory only.	PFE' s Days Inventory Range Over the Past 10 Years Min: 111.21 Med: 229.24 Max: 344.63 Current: 224.38 111.21 - 344.63
Days Sales Outstanding	67.96	PFE's Days Sales Outstanding is ranked higher than 56% of the 624 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 75.48 vs. PFE: 67.96 ) Ranked among companies with meaningful Days Sales Outstanding only.	PFE' s Days Sales Outstanding Range Over the Past 10 Years Min: 61.09 Med: 71.29 Max: 106.89 Current: 67.96 61.09 - 106.89
Days Payable	102.92	PFE's Days Payable is ranked higher than 70% of the 571 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 71.85 vs. PFE: 102.92 ) Ranked among companies with meaningful Days Payable only.	PFE' s Days Payable Range Over the Past 10 Years Min: 73.72 Med: 108.56 Max: 179.46 Current: 102.92 73.72 - 179.46

Dividend & Buy Back

		vs industry	vs history
Dividend Yield	3.77	PFE's Dividend Yield is ranked higher than 86% of the 653 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.66 vs. PFE: 3.77 ) Ranked among companies with meaningful Dividend Yield only.	PFE' s Dividend Yield Range Over the Past 10 Years Min: 2.9 Med: 3.67 Max: 10.4 Current: 3.77 2.9 - 10.4
Dividend Payout	1.18	PFE's Dividend Payout is ranked lower than 74% of the 393 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 0.34 vs. PFE: 1.18 ) Ranked among companies with meaningful Dividend Payout only.	PFE' s Dividend Payout Range Over the Past 10 Years Min: 0.58 Med: 0.77 Max: 1.18 Current: 1.18 0.58 - 1.18
Dividend Growth (3y)	7.70	PFE's Dividend Growth (3y) is ranked lower than 51% of the 283 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 8.10 vs. PFE: 7.70 ) Ranked among companies with meaningful Dividend Growth (3y) only.	PFE' s Dividend Growth (3y) Range Over the Past 10 Years Min: -14.7 Med: 12.7 Max: 22.6 Current: 7.7 -14.7 - 22.6
Forward Dividend Yield	3.98	PFE's Forward Dividend Yield is ranked higher than 86% of the 598 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.65 vs. PFE: 3.98 ) Ranked among companies with meaningful Forward Dividend Yield only.	N/A
Yield on cost (5-Year)	5.64	PFE's Yield on cost (5-Year) is ranked higher than 88% of the 782 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 2.18 vs. PFE: 5.64 ) Ranked among companies with meaningful Yield on cost (5-Year) only.	PFE' s Yield on cost (5-Year) Range Over the Past 10 Years Min: 4.34 Med: 5.49 Max: 15.57 Current: 5.64 4.34 - 15.57
3-Year Average Share Buyback Ratio	1.80	PFE's 3-Year Average Share Buyback Ratio is ranked higher than 96% of the 433 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: -4.40 vs. PFE: 1.80 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.	PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years Min: -17.6 Med: -4 Max: 7.2 Current: 1.8 -17.6 - 7.2

Valuation & Return

		vs industry	vs history
Price/Projected FCF	1.44	PFE's Price/Projected FCF is ranked higher than 74% of the 315 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 2.83 vs. PFE: 1.44 ) Ranked among companies with meaningful Price/Projected FCF only.	PFE' s Price/Projected FCF Range Over the Past 10 Years Min: 0.62 Med: 1.07 Max: 6.59 Current: 1.44 0.62 - 6.59
Price/Median PS Value	1.04	PFE's Price/Median PS Value is ranked higher than 59% of the 641 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.12 vs. PFE: 1.04 ) Ranked among companies with meaningful Price/Median PS Value only.	PFE' s Price/Median PS Value Range Over the Past 10 Years Min: 0.6 Med: 1.13 Max: 2.73 Current: 1.04 0.6 - 2.73
Earnings Yield (Greenblatt) (%)	4.89	PFE's Earnings Yield (Greenblatt) (%) is ranked higher than 66% of the 762 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 3.20 vs. PFE: 4.89 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.	PFE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years Min: 3.5 Med: 6.9 Max: 14.9 Current: 4.89 3.5 - 14.9
Forward Rate of Return (Yacktman) (%)	3.10	PFE's Forward Rate of Return (Yacktman) (%) is ranked lower than 59% of the 342 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 8.71 vs. PFE: 3.10 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.	PFE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years Min: 2.8 Med: 12.5 Max: 22.8 Current: 3.1 2.8 - 22.8

More Statistics

Revenue (TTM) (Mil) $	52,824
EPS (TTM) $	1.16
Beta	1.02
Short Percentage of Float	0.55%
52-Week Range $	28.34 - 37.39
Shares Outstanding (Mil)	6,068.36

Analyst Estimate

	Dec17	Dec18	Dec19
Revenue (Mil $)	53,473	53,733	53,007
EPS ($)	2.58	2.78	2.74
EPS w/o NRI ($)	2.58	2.78	2.74
EPS Growth Rate (3Y to 5Y Estimate)	6.10%
Dividends Per Share ($)	1.27	1.79	1.48

» More Articles for PFE

Headlines

Articles On GuruFocus.com

US Market Indexes Regain Some of Their Losses on Wednesday Feb 02 2017

A Would-Be Dividend Aristocrat With a 3.5% Dividend Yield Jan 24 2017

US Market Indexes Lower on Monday Jan 24 2017

BioCorRx Receives New Funding for Opioid Drug Jan 22 2017

Forester Value Fund Quarterly Update Jan 10 2017

Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Jan 10 2017

Kevin O’Leary’s Top 10 Quality Dividend Stocks Dec 29 2016

US Market Indexes Higher for the Week Dec 24 2016

Health Care Companies Showing Good Defensive Potential Dec 22 2016

9 Stocks Ray Dalio Continues to Buy Dec 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles

Financial Strength : 6/10

Profitability & Growth : 6/10

Financials

Warning Signs

Guru Trades

PFE Guru Trades in Q1 2016

PFE Guru Trades in Q2 2016

PFE Guru Trades in Q3 2016

PFE Guru Trades in Q4 2016

Insider Trades

Latest Guru Trades with PFE

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Top Ranked Articles about Pfizer Inc

Ratios

Dividend & Buy Back

Valuation & Return

More Statistics

Analyst Estimate

Headlines

Personalized Checklist

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles

Financial Strength : 6/10

Profitability & Growth : 6/10

Financials .earnings_date { color: #000000; font-size: 12px; font-weight: normal; }

Warning Signs

Guru Trades

PFE Guru Trades in Q1 2016

PFE Guru Trades in Q2 2016

PFE Guru Trades in Q3 2016

PFE Guru Trades in Q4 2016

Insider Trades

Latest Guru Trades with PFE

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Top Ranked Articles about Pfizer Inc

Ratios

Dividend & Buy Back

Valuation & Return

More Statistics

Analyst Estimate

Headlines

Personalized Checklist

Financials